HC Wainwright Issues Pessimistic Forecast for Barinthus Biotherapeutics (NASDAQ:BRNS) Stock Price

Barinthus Biotherapeutics (NASDAQ:BRNS) had its price objective dropped by HC Wainwright from $5.00 to $3.00 in a research report issued on Monday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. HC Wainwright’s price objective indicates a potential upside of 191.26% from the stock’s previous close.

Barinthus Biotherapeutics Price Performance

Shares of NASDAQ:BRNS opened at $1.03 on Monday. Barinthus Biotherapeutics has a 1 year low of $0.80 and a 1 year high of $4.16. The company has a market cap of $41.43 million, a PE ratio of -0.69 and a beta of -0.81. The stock’s 50-day moving average is $1.09 and its 200 day moving average is $1.25.

Barinthus Biotherapeutics (NASDAQ:BRNS) last posted its earnings results on Wednesday, November 6th. The company reported ($0.21) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.44) by $0.23. The firm had revenue of $14.97 million for the quarter. During the same quarter last year, the business earned ($0.37) EPS. Analysts expect that Barinthus Biotherapeutics will post -1.52 EPS for the current fiscal year.

About Barinthus Biotherapeutics

Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company's development pipeline includes VTP-300, an immunotherapeutic candidate under phase 2 studies as a potential component of a functional cure for chronic hepatitis B virus (HBV) infection; VTP-200, a non-surgical product candidate under phase 2 studies for treating persistent high-risk human papillomavirus (HPV) infection; VTP-1000, an autoimmune preclinical candidate designed to treat patients with celiac disease; VTP-1100 product candidate to target HPV16+ cancers; and VTP-850/850, a second-generation immunotherapeutic candidate under phase 2 studies to treat recurrent prostate cancer.